Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded by StockNews.com to “Sell”

StockNews.com downgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.

Separately, HC Wainwright reissued a “neutral” rating on shares of Oramed Pharmaceuticals in a report on Monday, September 9th.

Oramed Pharmaceuticals Trading Up 1.2 %

Shares of Oramed Pharmaceuticals stock opened at $2.44 on Friday. The business’s fifty day simple moving average is $2.38 and its 200 day simple moving average is $2.41. Oramed Pharmaceuticals has a 12 month low of $2.00 and a 12 month high of $3.67. The firm has a market capitalization of $98.36 million, a P/E ratio of 22.18 and a beta of 1.70.

Hedge Funds Weigh In On Oramed Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. BML Capital Management LLC raised its stake in shares of Oramed Pharmaceuticals by 62.1% in the third quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock valued at $5,334,000 after buying an additional 837,153 shares during the period. Murchinson Ltd. raised its stake in Oramed Pharmaceuticals by 23.2% in the 2nd quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock valued at $4,369,000 after acquiring an additional 320,495 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Oramed Pharmaceuticals during the third quarter valued at about $272,000. Renaissance Technologies LLC boosted its position in Oramed Pharmaceuticals by 89.0% during the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 108,700 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of Oramed Pharmaceuticals in the second quarter worth about $40,000. Hedge funds and other institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.